Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroTARGET biomarker study in metastatic renal cell carcinoma treated with targeted therapy
NL-OMON34570Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sunitinib and sorafenib in renal cell carcinoma (RCC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Therapy response. Started Aug 2011; status: recruiting.
02
Drugs
sunitinibsorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON34570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34570.